

## Supplementary files

Table S1 qRT-PCR primer sequence

Gene name	Forward primer (5'-3')	Reverse primer (3'-5')
<i>Actin-1</i>	GCTCTTGCCCCATCAACCAT	GCCGGACTCGTCGTATTCTT
<i>Elo-6</i>	AATCTCTGGAATGCGGGTCTTGC	CGGCTGAAGAACTCGTGGAGAAG
<i>Gpx-7</i>	ACAGGGTGGAACCTTTTTTCGATGC	ATACCATGCATACCTCGCCACAAC
<i>Gpx-8</i>	ACTGGGCGACTCTATCGGGATATTAG	CGTAAGTCAATTTGTCCTTCGGCAAG
<i>F54C8.1</i>	GCTCAAGTTACGGCGAGTAGTGG	TGCCTTCATCGCTCTATCAAGTGC
<i>Y39G8B.1</i>	CCAACTTCACCCACAGCCAGATC	AGTACCCGACCACCACAATACCC
<i>Fat-5</i>	CCAAGCCTGAACCTGATGTCCAAG	CGAAGCAGAAGATTCCGACCAAGG
<i>Pod-2</i>	TGTCTACGCCACTGCCGAGTC	TCGCCATTCATCACACGCTTATCC
<i>Fasn-1</i>	TCGGGTCGTGTCGGGTGAAG	CCTGAGTTGTCCGTCGTCTTGTC
<i>Bec-1</i>	GAAGCCGAACGTCAATATGCAGAAG	TCACCAACAATTCCATCAACCCAAATG




Fig. S1 Statistical histogram of the number of differential genes between GSP-E treatments and control




Fig. S2 Cluster heat map of differentially expressed genes between GSP-E treatments and control




Fig. S3 KEGG enrichment scatter plot in GSP-E treatment groups




Fig. S4 Heat map of the differential metabolites between ginkgo seed powder and GSP-E




Fig. S5 Heat map of the differential metabolites between ginkgo seed powder and GSP-E




Fig. S6 Nile Red staining

A. The 0 mg/mL control group. B. The 20 mg/mL treatment group.